Cencora, one of the largest pharmaceutical distribution companies in the United States, is deploying artificial intelligence to sharpen how it anticipates and responds to drug demand across its network.
Demand sensing represents a significant evolution beyond traditional forecasting, using real-time data signals to predict short-term inventory needs with far greater accuracy than older methods allowed.
At LogiPharma USA 2026, industry leaders gathered to examine how pharmaceutical supply chains can better integrate technology to reduce waste, improve availability, and serve patients more reliably.
PAXAFE’s Mark Talens emerged as a key voice at the event, arguing that supply chain visibility requires meaningful context before artificial intelligence can deliver its full potential value.
Talens explained that shared distribution visibility offers pharma companies some of their greatest opportunities, particularly when data is structured and interpreted with proper operational understanding.
Without that contextual foundation, AI tools risk generating misleading signals that could result in over-ordering, stock shortages, or misaligned logistics across complex pharmaceutical networks.
The pharmaceutical supply chain operates under uniquely demanding conditions, where temperature control, regulatory compliance, and patient safety concerns make errors far more consequential than in other industries.
AI-driven demand sensing tools aim to process vast streams of data, including sales trends, seasonal patterns, and distribution signals, to help companies like Cencora stay ahead of shifting requirements.
The approach reflects a broader industry push to move beyond reactive supply chain management and toward predictive models capable of absorbing disruption with minimal impact on drug availability.
As pharmaceutical companies continue investing in digital infrastructure, the conversation at events like LogiPharma USA 2026 is shifting from whether to adopt AI to how best to implement it responsibly and effectively.